Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer’s disease.

The interim study included 24 patients who were divided into three groups: a sham stimulation control group, a low-frequency treatment group and a high-frequency treatment group.

Each subject received treatment over eight weeks, and the efficacy of the treatment was evaluated both during the trial and over the course of the subsequent eight-week period.

Treatment using deep TMS was well-tolerated by all subjects, with no side-effects.

Efficacy was evaluated using the Alzheimer’s Disease Assessment Scale – Cognitive test and a quality-of-life scale.

The results suggest that high-frequency treatment leads to improvement on Alzheimer’s disease assessment scales, whereas low-frequency and sham treatment do not.